NCT05874505View on ClinicalTrials.gov

"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

July 31, 2027

Conditions
Behcet's Uveitis
Interventions
DRUG

Adalimumab

Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15

DRUG

Tocilizumab

Tocilizumab 162 mg subcutaneous each week for 15 weeks

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER